Fully automatic biochemistry analyzer market seen reaching $4.5 billion by 2030

The fully automatic biochemistry analyzer market is projected to grow from $3.55 billion in 2025 to $4.5 billion by 2030 as labs and healthcare systems push harder into automation. Europe led the market in 2025, while rising lab funding and broader diagnostic demand are set to keep adoption growing.

Why it matters: - Fully automatic biochemistry analyzers are becoming more important as hospitals, clinical labs and research facilities need faster testing, higher throughput and more standardized results. - The market outlook points to steady demand for automated diagnostic tools as healthcare systems expand lab capacity and cut manual work. - The report’s growth forecast signals continued investment in lab automation across clinical diagnostics and research.

What happened: - The market was valued at $3.55 billion in 2025 and is projected to reach $3.72 billion in 2026. - The Business Research Company said the market is expected to grow to $4.5 billion by 2030, implying a 4.9% CAGR from 2026 to 2030. - Europe held the largest regional share of the fully automatic biochemistry analyzer market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report was released Aug. 7, 2026.

The details: - Historical growth has been supported by rising clinical laboratory testing volumes, more diagnostic infrastructure in hospitals and greater adoption of automated laboratory equipment. - Faster diagnostic results and the growing burden of chronic and metabolic disorders also helped support demand. - Forward growth is expected to come from large-scale diagnostic screenings, expanding diagnostic laboratory networks and pressure to run labs more cost-efficiently. - Pharmaceutical and biotech research activity is also contributing to demand. - Healthcare automation spending is another driver behind the forecast. - The market’s key trends include fully automated workflows, high-throughput clinical testing, integrated sample and reagent handling systems, broader use in decentralized diagnostics and a stronger focus on accuracy and standardization. - A fully automatic biochemistry analyzer performs biochemical tests with minimal human input. - The systems automate sample processing, reagent management and data analysis. - The automation reduces human error, lowers operating costs and supports high throughput and consistency. - The report says the market for fully automatic biochemistry analyzers will benefit from growth in clinical and research laboratories worldwide. - Those labs have expanded because of more funding for biomedical research, clinical trials and personalized medicine initiatives. - Public and private investment, along with grant funding, has supported that expansion. - IQVIA reported that funding for clinical and research laboratories reached a decade-high $102 billion in 2024, up from $71 billion in 2023. - The report says that funding increase reflects expanding lab infrastructure and capabilities.

Between the lines: - The forecast suggests the category is maturing, with growth still positive but slower than in earlier phases. - Demand appears tied less to one breakthrough and more to broad structural shifts in diagnostics, research and lab efficiency. - The emphasis on decentralised diagnostics and integrated workflows suggests buyers want systems that can fit into more distributed healthcare models.

What's next: - Market growth is expected to continue through 2030 as lab networks expand and automation adoption widens. - The report highlights more use of Excel-based forecasting dashboards, TAM analysis, company scoring matrices, market hotspots infographics and updated graphics in its 2026 edition. - The Business Research Company is offering a free sample of the report and the full market report.